Insider transactions

EDGAR

SANA BIOTECHNOLOGY, INC.

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-16.

Open-market purchases (code P)
0 transactions, — shares
Open-market sales (code S)
0 transactions, — shares

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–45 of 45

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-10-05 Filed 2026-10-06Bishop Hans Edgar Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)8,680.000.00
0

Derived: shares × price per share. Exact value 0.0000.

5,863,480.00Direct (D) No
F1
  • F1 Consists of fully vested restricted stock units.
Open filing 0001480212-26-000010 Read from the filing’s XML Dispute this row
2026-08-27 Filed 2026-08-27PATEL DHAVALKUMAR DHIRAJLAL Officer: EVP, Chief Scientific Officer
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)41,158.004.11
169,159.38

Derived: shares × price per share. Exact value 169159.3800.

183,352.00Direct (D) No— Open filing 0002115339-26-000004 Read from the filing’s XML Dispute this row
2026-08-26 Filed 2026-08-27PATEL DHAVALKUMAR DHIRAJLAL Officer: EVP, Chief Scientific Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)125,000.000.00
0

Derived: shares × price per share. Exact value 0.0000.

224,510.00Direct (D) No— Open filing 0002115339-26-000004 Read from the filing’s XML Dispute this row
2026-08-26 Filed 2026-08-27PATEL DHAVALKUMAR DHIRAJLAL Officer: EVP, Chief Scientific Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Common Stock (125,000.00)
Disposed (D)125,000.000.00
0

Derived: shares × price per share. Exact value 0.0000.

250,000.00Direct (D) No
F1, F2
  • F1 Each restricted stock unit represents a contingent right to receive one share of Sana Biotechology, Inc. (Sana) common stock.
  • F2 The award vested as to 25% of the restricted stock units on each of August 26, 2025 and 2026, and the remaining restricted stock units will vest in two equal installments on each of August 26, 2027 and 2028, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.
Open filing 0002115339-26-000004 Read from the filing’s XML Dispute this row
2026-07-06 Filed 2026-07-07Bishop Hans Edgar Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)6,297.000.00
0

Derived: shares × price per share. Exact value 0.0000.

5,854,800.00Direct (D) No
F1
  • F1 Consists of fully vested restricted stock units.
Open filing 0001480212-26-000008 Read from the filing’s XML Dispute this row
2026-06-04 Filed 2026-06-05Seitz Michelle Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (90,000.00) — exercise price 2.96
Acquired (A)90,000.000.00
0

Derived: shares × price per share. Exact value 0.0000.

90,000.00Direct (D) No
F1
  • F1 The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 4, 2027 and (ii) immediately prior to the 2027 annual meeting of stockholders of Sana Biotechnology, Inc. (Sana), provided that the reporting person provides continuous service to Sana through such date.
Open filing 0001836301-26-000014 Read from the filing’s XML Dispute this row
2026-06-04 Filed 2026-06-05REICIN ALISE Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (90,000.00) — exercise price 2.96
Acquired (A)90,000.000.00
0

Derived: shares × price per share. Exact value 0.0000.

90,000.00Direct (D) No
F1
  • F1 The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 4, 2027 and (ii) immediately prior to the 2027 annual meeting of stockholders of Sana Biotechnology, Inc. (Sana), provided that the reporting person provides continuous service to Sana through such date.
Open filing 0001757533-26-000011 Read from the filing’s XML Dispute this row
2026-06-04 Filed 2026-06-05Mulligan Richard Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (90,000.00) — exercise price 2.96
Acquired (A)90,000.000.00
0

Derived: shares × price per share. Exact value 0.0000.

90,000.00Direct (D) No
F1
  • F1 The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 4, 2027 and (ii) immediately prior to the 2027 annual meeting of stockholders of Sana Biotechnology, Inc. (Sana), provided that the reporting person provides continuous service to Sana through such date.
Open filing 0001376247-26-000002 Read from the filing’s XML Dispute this row
2026-06-04 Filed 2026-06-05NELSEN ROBERT Director · 10% owner
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (90,000) — exercise price 2.96
Acquired (A)90,0000—90,000Direct (D) No
F1
  • F1 The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 4, 2027 and (ii) immediately prior to the 2027 annual meeting of stockholders of Sana Biotechnology, Inc. (Sana), provided that the reporting person provides continuous service to Sana through such date
Open filing 0001770121-26-000003 Read from the filing’s XML Dispute this row
2026-06-04 Filed 2026-06-05Rosiello Robert L. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (90,000.00) — exercise price 2.96
Acquired (A)90,000.000.00
0

Derived: shares × price per share. Exact value 0.0000.

90,000.00Direct (D) No
F1
  • F1 The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 4, 2027 and (ii) immediately prior to the 2027 annual meeting of stockholders of Sana Biotechnology, Inc. (Sana), provided that the reporting person provides continuous service to Sana through such date.
Open filing 0001645041-26-000002 Read from the filing’s XML Dispute this row
2026-06-04 Filed 2026-06-05Yang Patrick Y Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (90,000.00) — exercise price 2.96
Acquired (A)90,000.000.00
0

Derived: shares × price per share. Exact value 0.0000.

90,000.00Direct (D) No
F1
  • F1 The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 4, 2027 and (ii) immediately prior to the 2027 annual meeting of stockholders of Sana Biotechnology, Inc. (Sana), provided that the reporting person provides continuous service to Sana through such date.
Open filing 0001309988-26-000002 Read from the filing’s XML Dispute this row
2026-06-04 Filed 2026-06-05Bishop Hans Edgar Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (90,000.00) — exercise price 2.96
Acquired (A)90,000.000.00
0

Derived: shares × price per share. Exact value 0.0000.

90,000.00Direct (D) No
F1
  • F1 The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 4, 2027 and (ii) immediately prior to the 2027 annual meeting of stockholders of Sana Biotechnology, Inc. (Sana), provided that the reporting person provides continuous service to Sana through such date.
Open filing 0001480212-26-000006 Read from the filing’s XML Dispute this row
2026-06-04 Filed 2026-06-05Bilenker Joshua H. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (90,000.00) — exercise price 2.96
Acquired (A)90,000.000.00
0

Derived: shares × price per share. Exact value 0.0000.

90,000.00Direct (D) No
F1
  • F1 The option vests and becomes exercisable as to 100% of the underlying shares on the earlier of (i) June 4, 2027 and (ii) immediately prior to the 2027 annual meeting of stockholders of Sana Biotechnology, Inc. (Sana), provided that the reporting person provides continuous service to Sana through such date.
Open filing 0001612312-26-000002 Read from the filing’s XML Dispute this row
2026-04-06 Filed 2026-04-08Bishop Hans Edgar Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)7,763.000.00
0

Derived: shares × price per share. Exact value 0.0000.

5,848,503.00Direct (D) No
F1
  • F1 Consists of fully vested restricted stock units.
Open filing 0001480212-26-000004 Read from the filing’s XML Dispute this row
2026-03-09 Filed 2026-03-10Harr Steve Director · Officer: President CEO
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)11,526.003.13
36,076.38

Derived: shares × price per share. Exact value 36076.3800.

7,957,070.00Direct (D) No— Open filing 0001627387-26-000004 Read from the filing’s XML Dispute this row
2026-03-09 Filed 2026-03-10Harr Steve Director · Officer: President CEO
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)12,819.003.10
39,738.9

Derived: shares × price per share. Exact value 39738.9000.

7,944,251.00Direct (D) No— Open filing 0001627387-26-000004 Read from the filing’s XML Dispute this row
2026-03-09 Filed 2026-03-10Wyrick Susan D. Officer: See Remarks
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)3,342.003.13
10,460.46

Derived: shares × price per share. Exact value 10460.4600.

197,241.00Direct (D) No— Open filing 0001568605-26-000008 Read from the filing’s XML Dispute this row
2026-03-09 Filed 2026-03-10Wyrick Susan D. Officer: See Remarks
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)1,045.003.10
3,239.5

Derived: shares × price per share. Exact value 3239.5000.

196,196.00Direct (D) No— Open filing 0001568605-26-000008 Read from the filing’s XML Dispute this row
2026-03-07 Filed 2026-03-10Harr Steve Director · Officer: President CEO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)50,000.000.00
0

Derived: shares × price per share. Exact value 0.0000.

7,968,596.00Direct (D) No— Open filing 0001627387-26-000004 Read from the filing’s XML Dispute this row
2026-03-07 Filed 2026-03-10Harr Steve Director · Officer: President CEO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Common Stock (50,000.00)
Disposed (D)50,000.000.00
0

Derived: shares × price per share. Exact value 0.0000.

100,000.00Direct (D) No
F2, F4
  • F2 Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. (Sana) common stock.
  • F4 The award vested as to 25% of the restricted stock units on each of March 7, 2025 and 2026, and the remaining restricted stock units will vest in two equal installments on each of March 7, 2027 and 2028, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.
Open filing 0001627387-26-000004 Read from the filing’s XML Dispute this row
2026-03-07 Filed 2026-03-10Wyrick Susan D. Officer: See Remarks
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)3,250.000.00
0

Derived: shares × price per share. Exact value 0.0000.

200,583.00Direct (D) No— Open filing 0001568605-26-000008 Read from the filing’s XML Dispute this row
2026-03-07 Filed 2026-03-10Wyrick Susan D. Officer: See Remarks
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Common Stock (3,250.00)
Disposed (D)3,250.000.00
0

Derived: shares × price per share. Exact value 0.0000.

6,500.00Direct (D) No
F1, F3
  • F1 Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. (Sana) common stock.
  • F3 The award vested as to 25% of the restricted stock units on each of March 7, 2025 and 2026, and the remaining restricted stock units will vest in two equal installments on each of March 7, 2027 and 2028, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.
Open filing 0001568605-26-000008 Read from the filing’s XML Dispute this row
2026-03-06 Filed 2026-03-10Harr Steve Director · Officer: President CEO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)41,666.000.00
0

Derived: shares × price per share. Exact value 0.0000.

7,918,596.00Direct (D) No— Open filing 0001627387-26-000004 Read from the filing’s XML Dispute this row
2026-03-06 Filed 2026-03-10Harr Steve Director · Officer: President CEO
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Common Stock (41,666.00)
Disposed (D)41,666.000.00
0

Derived: shares × price per share. Exact value 0.0000.

125,001.00Direct (D) No
F2, F3
  • F2 Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. (Sana) common stock.
  • F3 The award vested as to 25% of the restricted stock units on March 6, 2026, and the remaining restricted stock units will vest in three equal installments on each of March 6, 2027, 2028 and 2029, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.
Open filing 0001627387-26-000004 Read from the filing’s XML Dispute this row
2026-03-06 Filed 2026-03-10Wyrick Susan D. Officer: See Remarks
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)10,416.000.00
0

Derived: shares × price per share. Exact value 0.0000.

197,333.00Direct (D) No— Open filing 0001568605-26-000008 Read from the filing’s XML Dispute this row
2026-03-06 Filed 2026-03-10Wyrick Susan D. Officer: See Remarks
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Common Stock (10,416.00)
Disposed (D)10,416.000.00
0

Derived: shares × price per share. Exact value 0.0000.

31,251.00Direct (D) No
F1, F2
  • F1 Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. (Sana) common stock.
  • F2 The award vested as to 25% of the restricted stock units on March 6, 2026, and the remaining restricted stock units will vest in three equal installments on each of March 6, 2027, 2028 and 2029, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.
Open filing 0001568605-26-000008 Read from the filing’s XML Dispute this row
2026-03-05 Filed 2026-03-06Wyrick Susan D. Officer: See Remarks
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Units — underlying Common Stock (45,833.00)
Acquired (A)45,833.000.00
0

Derived: shares × price per share. Exact value 0.0000.

45,833.00Direct (D) No
F1, F2
  • F1 Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. (Sana) common stock.
  • F2 The restricted stock units vest in four equal installments on each of March 5, 2027, 2028, 2029 and 2030, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.
Open filing 0001568605-26-000006 Read from the filing’s XML Dispute this row
2026-03-05 Filed 2026-03-06Wyrick Susan D. Officer: See Remarks
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (206,250.00) — exercise price 3.41
Acquired (A)206,250.000.00
0

Derived: shares × price per share. Exact value 0.0000.

206,250.00Direct (D) No
F3
  • F3 The option vests and becomes exercisable as to 25% of the underlying shares on March 5, 2027 and in 36 equal monthly installments thereafter, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.
Open filing 0001568605-26-000006 Read from the filing’s XML Dispute this row
2026-03-05 Filed 2026-03-06Harr Steve Director · Officer: President CEO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Units — underlying Common Stock (200,000.00)
Acquired (A)200,000.000.00
0

Derived: shares × price per share. Exact value 0.0000.

200,000.00Direct (D) No
F1, F2
  • F1 Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. (Sana) common stock.
  • F2 The restricted stock units vest in four equal installments on each of March 5, 2027, 2028, 2029 and 2030, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.
Open filing 0001627387-26-000002 Read from the filing’s XML Dispute this row
2026-03-05 Filed 2026-03-06Harr Steve Director · Officer: President CEO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (900,000.00) — exercise price 3.41
Acquired (A)900,000.000.00
0

Derived: shares × price per share. Exact value 0.0000.

900,000.00Direct (D) No
F3
  • F3 The option vests and becomes exercisable as to 25% of the underlying shares on March 5, 2027 and in 36 equal monthly installments thereafter, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.
Open filing 0001627387-26-000002 Read from the filing’s XML Dispute this row
2026-03-03 Filed 2026-03-04Wyrick Susan D. Officer: See Remarks
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)491.003.91
1,919.81

Derived: shares × price per share. Exact value 1919.8100.

186,917.00Direct (D) No— Open filing 0001568605-26-000004 Read from the filing’s XML Dispute this row
2026-03-02 Filed 2026-03-04Wyrick Susan D. Officer: See Remarks
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)1,525.000.00
0

Derived: shares × price per share. Exact value 0.0000.

187,408.00Direct (D) No— Open filing 0001568605-26-000004 Read from the filing’s XML Dispute this row
2026-03-02 Filed 2026-03-04Wyrick Susan D. Officer: See Remarks
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Common Stock (1,525.00)
Disposed (D)1,525.000.00
0

Derived: shares × price per share. Exact value 0.0000.

1,525.00Direct (D) No
F1, F2
  • F1 Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. (Sana) common stock.
  • F2 The award vested as to 25% of the restricted stock units on each of March 2, 2024, 2025 and 2026, and the remaining restricted stock units will vest on March 2, 2027, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through such date.
Open filing 0001568605-26-000004 Read from the filing’s XML Dispute this row
2026-02-17 Filed 2026-02-18Piper Brian Officer: EVP, Chief Financial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Restricted Stock Units — underlying Common Stock (200,000.00)
Acquired (A)200,000.000.00
0

Derived: shares × price per share. Exact value 0.0000.

200,000.00Direct (D) No
F1, F2
  • F1 Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. (Sana) common stock.
  • F2 The restricted stock units vest in four equal installments on each of February 17, 2027, 2028, 2029 and 2030, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.
Open filing 0001665924-26-000008 Read from the filing’s XML Dispute this row
2026-02-17 Filed 2026-02-18Piper Brian Officer: EVP, Chief Financial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (900,000.00) — exercise price 3.85
Acquired (A)900,000.000.00
0

Derived: shares × price per share. Exact value 0.0000.

900,000.00Direct (D) No
F3
  • F3 The option vests and becomes exercisable as to 25% of the underlying shares on February 17, 2027 and in 36 equal monthly installments thereafter, provided that the reporting person provides continuous service to Sana as an employee, consultant, director or officer of Sana through each such date.
Open filing 0001665924-26-000008 Read from the filing’s XML Dispute this row
2026-01-05 Filed 2026-01-06Wyrick Susan D. Officer: See Remarks
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)2,407.004.27
10,277.89

Derived: shares × price per share. Exact value 10277.8900.

185,883.00Direct (D) No— Open filing 0001568605-26-000002 Read from the filing’s XML Dispute this row
2026-01-05 Filed 2026-01-06Bishop Hans Edgar Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Common Stock
Acquired (A)6,157.000.00
0

Derived: shares × price per share. Exact value 0.0000.

5,840,740.00Direct (D) No
F1
  • F1 Consists of fully vested restricted stock units.
Open filing 0001480212-26-000002 Read from the filing’s XML Dispute this row
2026-01-02 Filed 2026-01-06Wyrick Susan D. Officer: See Remarks
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)7,500.000.00
0

Derived: shares × price per share. Exact value 0.0000.

188,290.00Direct (D) No— Open filing 0001568605-26-000002 Read from the filing’s XML Dispute this row
2026-01-02 Filed 2026-01-06Wyrick Susan D. Officer: See Remarks
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Common Stock (7,500.00)
Disposed (D)7,500.00——0.00Direct (D) No
F1, F2
  • F1 Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. common stock.
  • F2 The award vested as to 40% of the restricted stock units on January 2, 2025 and 60% of the restricted stock units on January 2, 2026.
Open filing 0001568605-26-000002 Read from the filing’s XML Dispute this row
2025-12-15 Filed 2025-12-16Wyrick Susan D. Officer: See Remarks
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)873.005.22
4,557.06

Derived: shares × price per share. Exact value 4557.0600.

180,790.00Direct (D) No— Open filing 0001568605-25-000007 Read from the filing’s XML Dispute this row
2025-12-13 Filed 2025-12-16Wyrick Susan D. Officer: See Remarks
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)3,400.000.00
0

Derived: shares × price per share. Exact value 0.0000.

181,663.00Direct (D) No— Open filing 0001568605-25-000007 Read from the filing’s XML Dispute this row
2025-12-13 Filed 2025-12-16Wyrick Susan D. Officer: See Remarks
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Common Stock (3,400.00)
Disposed (D)3,400.00——0.00Direct (D) No
F1, F2
  • F1 Each restricted stock unit represents a contingent right to receive one share of Sana Biotechnology, Inc. common stock.
  • F2 The award vested as to 100% of the restricted stock units on December 13, 2025.
Open filing 0001568605-25-000007 Read from the filing’s XML Dispute this row
2025-12-04 Filed 2025-12-05Wyrick Susan D. Officer: See Remarks
F

Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3

Common Stock
Disposed (D)2,565.004.44
11,388.6

Derived: shares × price per share. Exact value 11388.6000.

178,263.00Direct (D) No— Open filing 0001568605-25-000005 Read from the filing’s XML Dispute this row
2025-12-03 Filed 2025-12-05Wyrick Susan D. Officer: See Remarks
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)10,000.000.00
0

Derived: shares × price per share. Exact value 0.0000.

180,828.00Direct (D) No
F3
  • F3 Includes 3,000 shares acquired on November 14, 2025 pursuant to the ESPP.
Open filing 0001568605-25-000005 Read from the filing’s XML Dispute this row
2025-12-03 Filed 2025-12-05Wyrick Susan D. Officer: See Remarks
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Restricted Stock Units — underlying Common Stock (10,000.00)
Disposed (D)10,000.000.00
0

Derived: shares × price per share. Exact value 0.0000.

0.00Direct (D) No
F4, F7
  • F4 Each restricted stock unit represents a contingent right to receive one share of Sana common stock.
  • F7 The restricted stock units vested in two equal installments on each of June 3, 2025 and December 3, 2025.
Open filing 0001568605-25-000005 Read from the filing’s XML Dispute this row

Institutional holders (Form 13F)

Quarter ending 2026-09-30: 7,211 filings read, the latest filed 2026-11-13. Prior quarter ending 2026-06-30: 9,150 filings read.

Showing 1–50 of 148

Institutional holders, largest position first, as filed
ManagerShares or principalValue as filedChange from the prior quarterSource
FMR LLC Partly reported under another manager37,293,854 SH108,711,585 dollarsLower by 135,661 Prior quarter: 37,429,515Open filing 0000315066-26-002964 Filed 2026-11-10 Dispute this row
BlackRock, Inc. Partly reported under another manager16,384,234 SH47,760,044 dollarsLower by 290,939 Prior quarter: 16,675,173Open filing 0002012383-26-003985 Filed 2026-11-13 Dispute this row
STATE STREET CORP Partly reported under another manager9,579,479 SH27,924,181 dollarsLower by 1,623,655 Prior quarter: 11,203,134Open filing 0000093751-26-000747 Filed 2026-11-12 Dispute this row
VANGUARD CAPITAL MANAGEMENT LLC 8,611,172 SH25,101,566 dollarsHigher by 235,751 Prior quarter: 8,375,421Open filing 0002100119-26-001711 Filed 2026-11-13 Dispute this row
GEODE CAPITAL MANAGEMENT, LLC Partly reported under another manager4,650,990 SH13,560,202 dollarsLower by 26,969 Prior quarter: 4,677,959Open filing 0001214717-26-000012 Filed 2026-11-06 Dispute this row
MORGAN STANLEY Partly reported under another manager3,022,371 SH8,810,211 dollarsHigher by 1,882,589 Prior quarter: 1,139,782Open filing 0000895421-26-000309 Filed 2026-11-13 Dispute this row
Alphabet Inc. Partly reported under another manager2,812,500 SH8,212,500 dollarsUnchanged Prior quarter: 2,812,500Open filing 0001652044-26-000086 Filed 2026-11-06 Dispute this row
MARSHALL WACE, LLP Partly reported under another manager2,259,809 SH6,598,642 dollarsLower by 671,627 Prior quarter: 2,931,436Open filing 0001318757-26-000012 Filed 2026-11-13 Dispute this row
VANGUARD PORTFOLIO MANAGEMENT LLC 1,820,403 SH5,306,475 dollarsLower by 61,286 Prior quarter: 1,881,689Open filing 0002100121-26-001150 Filed 2026-11-13 Dispute this row
RENAISSANCE TECHNOLOGIES LLC Partly reported under another manager1,421,500 SH4,143,673 dollarsHigher by 190,400 Prior quarter: 1,231,100Open filing 0001037389-26-000062 Filed 2026-11-12 Dispute this row
VANGUARD FIDUCIARY TRUST CO 1,373,292 SH4,003,146 dollarsHigher by 135,855 Prior quarter: 1,237,437Open filing 0000933478-26-000017 Filed 2026-11-13 Dispute this row
UBS Group AG Partly reported under another manager1,116,060 SH3,253,316 dollarsHigher by 54,619 Prior quarter: 1,061,441Open filing 0001610520-26-000121 Filed 2026-11-10 Dispute this row
JPMORGAN CHASE CO Partly reported under another manager779,859 SH2,269,390 dollarsHigher by 2,561 Prior quarter: 777,298Open filing 0000019617-26-000404 Filed 2026-11-12 Dispute this row
HRT FINANCIAL LP 683,993 SH1,993 dollarsNot in the prior quarter’s filings read Open filing 0001475597-26-000249 Filed 2026-11-13 Dispute this row
DEUTSCHE BANK AG\ Partly reported under another manager618,741 SH1,806,724 dollarsLower by 26,346 Prior quarter: 645,087Open filing 0000948046-26-000083 Filed 2026-11-06 Dispute this row
Invesco Ltd. Partly reported under another manager497,374 SH1,449,846 dollarsLower by 6,888 Prior quarter: 504,262Open filing 0000914208-26-000462 Filed 2026-11-12 Dispute this row
Bank of New York Mellon Corp Partly reported under another manager434,767 SH1,267,345 dollarsLower by 42,775 Prior quarter: 477,542Open filing 0001390777-26-000121 Filed 2026-11-05 Dispute this row
Nuveen, LLC Partly reported under another manager352,605 SH1,027,844 dollarsLower by 17,117 Prior quarter: 369,722Open filing 0000930413-26-003284 Filed 2026-11-10 Dispute this row
Swiss National Bank 348,100 SH1,014,712 dollarsUnchanged Prior quarter: 348,100Open filing 0001582202-26-000008 Filed 2026-11-12 Dispute this row
Quadrature Capital Ltd Partly reported under another manager303,761 SH885,463 dollarsHigher by 226,705 Prior quarter: 77,056Open filing 0001651424-26-000014 Filed 2026-11-13 Dispute this row
DIMENSIONAL FUND ADVISORS LP Partly reported under another manager285,886 SH833,357 dollarsLower by 8,956 Prior quarter: 294,842Open filing 0000354204-26-001096 Filed 2026-11-04 Dispute this row
FRANKLIN TEMPLETON INC Partly reported under another manager261,144 SH668,529 dollarsNot in the prior quarter’s filings read Open filing 0000038777-26-000291 Filed 2026-11-12 Dispute this row
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP Partly reported under another manager246,670 SH719,043 dollarsHigher by 137,073 Prior quarter: 109,597Open filing 0001164508-26-000060 Filed 2026-11-13 Dispute this row
Rafferty Asset Management, LLC 237,091 SH691,120 dollarsHigher by 40,360 Prior quarter: 196,731Open filing 0001999371-26-025241 Filed 2026-11-13 Dispute this row
Squarepoint Ops LLC Partly reported under another manager236,005 SH687,955 dollarsHigher by 211,482 Prior quarter: 24,523Open filing 0001642575-26-000012 Filed 2026-11-09 Dispute this row
RHUMBLINE ADVISERS 214,751 SH625,988 dollarsLower by 8,661 Prior quarter: 223,412Open filing 0001115418-26-000015 Filed 2026-11-10 Dispute this row
SIMPLEX TRADING, LLC Option: Call 202,400 SH589,996 dollarsLower by 18,900 Prior quarter: 221,300Open filing 0001488542-26-000013 Filed 2026-11-04 Dispute this row
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM 181,749 SH529,798 dollarsUnchanged Prior quarter: 181,749Open filing 0001081019-26-000023 Filed 2026-11-13 Dispute this row
Clearstead Advisors, LLC Partly reported under another manager170,717 SH497,637 dollarsLower by 22 Prior quarter: 170,739Open filing 0000842775-26-000005 Filed 2026-11-06 Dispute this row
Russell Investments Group, Ltd. Partly reported under another manager156,971 SH457,569 dollarsLower by 17,816 Prior quarter: 174,787Open filing 0001193125-26-451241 Filed 2026-11-06 Dispute this row
VANGUARD ASSET MANAGEMENT, Ltd 140,692 SH410,117 dollarsHigher by 39,024 Prior quarter: 101,668Open filing 0001680208-26-000018 Filed 2026-11-13 Dispute this row
Banque Cantonale Vaudoise 140,000 SH408 dollarsHigher by 26,000 Prior quarter: 114,000Open filing 0001793755-26-000008 Filed 2026-11-12 Dispute this row
CITIGROUP INC Partly reported under another manager128,012 SH373,155 dollarsLower by 144,512 Prior quarter: 272,524Open filing 0000831001-26-000052 Filed 2026-11-04 Dispute this row
OPTIMIZE FINANCIAL INC. 125,358 SH365,419 dollarsLower by 14,859 Prior quarter: 140,217Open filing 0002033266-26-000008 Filed 2026-11-12 Dispute this row
BARCLAYS PLC Partly reported under another manager120,647 SH351,686 dollarsHigher by 71,290 Prior quarter: 49,357Open filing 0000312069-26-000241 Filed 2026-11-06 Dispute this row
Virtus Investment Advisers, LLC Partly reported under another manager118,408 SH345,159 dollarsLower by 3,681 Prior quarter: 122,089Open filing 0000019481-26-000011 Filed 2026-11-12 Dispute this row
GROUP ONE TRADING LLC 110,800 SH322,982 dollarsLower by 9,545 Prior quarter: 120,345Open filing 0000932540-26-000017 Filed 2026-11-10 Dispute this row
VOYA INVESTMENT MANAGEMENT LLC Partly reported under another manager95,448 SH278,231 dollarsHigher by 200 Prior quarter: 95,248Open filing 0001068837-26-000006 Filed 2026-11-10 Dispute this row
VIRGINIA RETIREMENT SYSTEMS ET Al Partly reported under another manager88,950 SH259,289 dollarsLower by 13,900 Prior quarter: 102,850Open filing 0001005354-26-000009 Filed 2026-10-28 Dispute this row
PROFUND ADVISORS LLC 83,705 SH244,000 dollarsLower by 15,797 Prior quarter: 99,502Open filing 0001129919-26-000005 Filed 2026-10-29 Dispute this row
Palumbo Wealth Management LLC 83,462 SH243,292 dollarsHigher by 23,689 Prior quarter: 59,773Open filing 0001951757-26-001936 Filed 2026-11-13 Dispute this row
Zurcher Kantonalbank (Zurich Cantonalbank) Partly reported under another manager82,393 SH240,176 dollarsUnchanged Prior quarter: 82,393Open filing 0001368163-26-000007 Filed 2026-11-10 Dispute this row
SCS Capital Management LLC 81,250 SH236,844 dollarsUnchanged Prior quarter: 81,250Open filing 0001303159-26-000007 Filed 2026-11-12 Dispute this row
Creative Planning Partly reported under another manager79,232 SH230,962 dollarsHigher by 18,584 Prior quarter: 60,648Open filing 0001540235-26-000006 Filed 2026-11-02 Dispute this row
LOS ANGELES CAPITAL MANAGEMENT LLC 76,088 SH221,796 dollarsLower by 117,195 Prior quarter: 193,283Open filing 0001177206-26-000010 Filed 2026-11-12 Dispute this row
Vanguard Global Advisers, LLC 75,590 SH220,345 dollarsHigher by 15,265 Prior quarter: 60,325Open filing 0001811242-26-000017 Filed 2026-11-13 Dispute this row
IEQ CAPITAL, LLC 67,539 SH196,876 dollarsLower by 61,253 Prior quarter: 128,792Open filing 0001779789-26-000005 Filed 2026-11-10 Dispute this row
Quinn Opportunity Partners LLC Partly reported under another manager60,100 SH175,192 dollarsUnchanged Prior quarter: 60,100Open filing 0001633275-26-000013 Filed 2026-11-10 Dispute this row
BNP PARIBAS FINANCIAL MARKETS Partly reported under another manager59,639 SH173,848 dollarsHigher by 189 Prior quarter: 59,450Open filing 0001166588-26-000012 Filed 2026-11-12 Dispute this row
State of New Jersey Common Pension Fund D 55,691 SH162,339 dollarsLower by 397 Prior quarter: 56,088Open filing 0001483066-26-000007 Filed 2026-11-05 Dispute this row
Managers in the prior quarter with no filing read for the latest

They may simply not have filed yet: absent from the latest quarter’s filings read is not the same as a position sold.

  • Flagship Pioneering, LLC 25,001,856 SH
  • RA CAPITAL MANAGEMENT, L.P. 18,750,000 SH
  • CANADA PENSION PLAN INVESTMENT BOARD 10,218,400 SH
  • BANK OF AMERICA CORP /DE/ 5,748,454 SH
  • Marex Group Ltd 3,989,100 SH
  • GOLDMAN SACHS GROUP INC 2,367,935 SH
  • Integral Health Asset Management, LLC 2,000,000 SH
  • TORONTO DOMINION BANK 1,972,381 SH
  • JACOBS LEVY EQUITY MANAGEMENT, INC 1,868,718 SH
  • NORTHERN TRUST CORP 1,604,084 SH
  • CHARLES SCHWAB INVESTMENT MANAGEMENT INC 1,379,181 SH
  • Sixth Street Partners Management Company, L.P. 1,379,181 SH
  • Woodline Partners LP 1,317,932 SH
  • AQR CAPITAL MANAGEMENT LLC 963,147 SH
  • Omega Fund Management, LLC 843,750 SH
  • Crestline Management, L.P. 755,736 SH
  • ArrowMark Colorado Holdings LLC 685,125 SH
  • MILLENNIUM MANAGEMENT LLC 653,503 SH
  • TWO SIGMA INVESTMENTS, LP 638,837 SH
  • Corient Private Wealth LP 628,100 SH
  • Point72 Asset Management, L.P. 595,091 SH
  • SUSQUEHANNA INTERNATIONAL GROUP, LLP 384,083 SH
  • BAKER BROS. ADVISORS LP 310,483 SH
  • UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC 284,472 SH
  • PRICE T ROWE ASSOCIATES INC /MD/ 282,916 SH
  • XTX Topco Ltd 226,590 SH
  • SUSQUEHANNA INTERNATIONAL GROUP, LLP 199,000 SH
  • ALLIANCEBERNSTEIN L.P. 186,945 SH
  • WELLS FARGO COMPANY/MN 173,546 SH
  • ALGERT GLOBAL LLC 168,569 SH
  • CITADEL ADVISORS LLC 161,178 SH
  • PEAK6 LLC 150,000 SH
  • SUSQUEHANNA INTERNATIONAL GROUP, LLP 148,200 SH
  • Sound Capital Solutions LLC 140,217 SH
  • Legal General Group Plc 136,181 SH
  • AMERIPRISE FINANCIAL INC 120,274 SH
  • HSBC HOLDINGS PLC 111,959 SH
  • MetLife Investment Management, LLC 109,959 SH
  • CITADEL ADVISORS LLC 109,000 SH
  • MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 107,424 SH
  • SG Americas Securities, LLC 95,039 SH
  • GILDER GAGNON HOWE CO LLC 89,960 SH
  • TUDOR INVESTMENT CORP ET AL 87,892 SH
  • VARCOV Co. 79,895 SH
  • STATE OF WISCONSIN INVESTMENT BOARD 72,241 SH
  • CITADEL ADVISORS LLC 71,700 SH
  • DRW Securities, LLC 66,249 SH
  • Jupiter Topco LLC 58,189 SH
  • Brevan Howard Capital Management LP 52,545 SH
  • D. E. Shaw Co., Inc. 40,090 SH
  • Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
  • A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
  • A change is the difference between two quarter-end snapshots, not a trade.
  • A position reported under another manager may also appear in that manager’s filing; rows are not added together.
  • Holdings the securities list cannot place with this company, or places ambiguously, are not shown.

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.

5% holders, newest event first, as filed
HolderPercent of classShares heldEvent dateFormSource
FMR LLC COMMON STOCK12.537,293,854.0009/30/2026 Filed 2026-11-05SCHEDULE 13G/AAmendment 4Open filing 0000315066-26-002831 Dispute this row
Abigail P. Johnson COMMON STOCK12.537,293,854.0009/30/2026 Filed 2026-11-05SCHEDULE 13G/AAmendment 4Open filing 0000315066-26-002831 Dispute this row
ARCH Venture Fund IX, L.P. Common Stock, par value $0.0001 per share15.345,860,68106/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 5Open filing 0001012975-26-000773 Dispute this row
ARCH Venture Fund IX Overage, L.P. Common Stock, par value $0.0001 per share15.345,860,68106/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 5Open filing 0001012975-26-000773 Dispute this row
ARCH Venture Fund X, L.P. Common Stock, par value $0.0001 per share15.345,860,68106/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 5Open filing 0001012975-26-000773 Dispute this row
ARCH Venture Fund X Overage, L.P. Common Stock, par value $0.0001 per share15.345,860,68106/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 5Open filing 0001012975-26-000773 Dispute this row
ARCH Venture Partners IX, L.P. Common Stock, par value $0.0001 per share15.345,860,68106/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 5Open filing 0001012975-26-000773 Dispute this row
ARCH Venture Partners IX Overage, L.P. Common Stock, par value $0.0001 per share15.345,860,68106/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 5Open filing 0001012975-26-000773 Dispute this row
ARCH Venture Partners X Overage, L.P. Common Stock, par value $0.0001 per share15.345,860,68106/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 5Open filing 0001012975-26-000773 Dispute this row
ARCH Venture Partners X, L.P. Common Stock, par value $0.0001 per share15.345,860,68106/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 5Open filing 0001012975-26-000773 Dispute this row
ARCH Venture Partners IX, LLC Common Stock, par value $0.0001 per share15.345,860,68106/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 5Open filing 0001012975-26-000773 Dispute this row
ARCH Venture Partners X, LLC Common Stock, par value $0.0001 per share15.345,860,68106/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 5Open filing 0001012975-26-000773 Dispute this row
Keith Crandell Common Stock, par value $0.0001 per share15.345,860,68106/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 5Open filing 0001012975-26-000773 Dispute this row
Clinton Bybee Common Stock, par value $0.0001 per share15.345,860,68106/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 5Open filing 0001012975-26-000773 Dispute this row
Robert Nelsen Common Stock, par value $0.0001 per share15.446,173,12506/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 5Open filing 0001012975-26-000773 Dispute this row
Steven Gillis Common Stock, par value $0.0001 per share15.345,860,68106/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 5Open filing 0001012975-26-000773 Dispute this row
Kristina Burow Common Stock, par value $0.0001 per share15.345,860,68106/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 5Open filing 0001012975-26-000773 Dispute this row
RA Capital Management, L.P. Common Stock, $0.0001 par value per share6.318,750,000.0005/14/2026 Filed 2026-05-21SCHEDULE 13GOpen filing 0001346824-26-000166 Dispute this row
Peter Kolchinsky Common Stock, $0.0001 par value per share6.318,750,000.0005/14/2026 Filed 2026-05-21SCHEDULE 13GOpen filing 0001346824-26-000166 Dispute this row
Rajeev Shah Common Stock, $0.0001 par value per share6.318,750,000.0005/14/2026 Filed 2026-05-21SCHEDULE 13GOpen filing 0001346824-26-000166 Dispute this row
RA Capital Healthcare Fund, L.P. Common Stock, $0.0001 par value per share6.318,750,000.0005/14/2026 Filed 2026-05-21SCHEDULE 13GOpen filing 0001346824-26-000166 Dispute this row
BlackRock, Inc. Common Stock5.113,643,30412/31/2025 Filed 2026-01-21SCHEDULE 13GOpen filing 0002012383-26-000786 Dispute this row
ARCH Venture Fund IX, L.P. Common Stock, par value $0.0001 per share17.245,860,68109/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 4Open filing 0001012975-25-000773 Dispute this row
ARCH Venture Fund IX Overage, L.P. Common Stock, par value $0.0001 per share17.245,860,68109/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 4Open filing 0001012975-25-000773 Dispute this row
ARCH Venture Fund X, L.P. Common Stock, par value $0.0001 per share17.245,860,68109/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 4Open filing 0001012975-25-000773 Dispute this row
ARCH Venture Fund X Overage, L.P. Common Stock, par value $0.0001 per share17.245,860,68109/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 4Open filing 0001012975-25-000773 Dispute this row
ARCH Venture Partners IX, L.P. Common Stock, par value $0.0001 per share17.245,860,68109/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 4Open filing 0001012975-25-000773 Dispute this row
ARCH Venture Partners IX Overage, L.P. Common Stock, par value $0.0001 per share17.245,860,68109/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 4Open filing 0001012975-25-000773 Dispute this row
ARCH Venture Partners X Overage, L.P. Common Stock, par value $0.0001 per share17.245,860,68109/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 4Open filing 0001012975-25-000773 Dispute this row
ARCH Venture Partners X, L.P. Common Stock, par value $0.0001 per share17.245,860,68109/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 4Open filing 0001012975-25-000773 Dispute this row
ARCH Venture Partners IX, LLC Common Stock, par value $0.0001 per share17.245,860,68109/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 4Open filing 0001012975-25-000773 Dispute this row
ARCH Venture Partners X, LLC Common Stock, par value $0.0001 per share17.245,860,68109/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 4Open filing 0001012975-25-000773 Dispute this row
Keith Crandell Common Stock, par value $0.0001 per share17.245,860,68109/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 4Open filing 0001012975-25-000773 Dispute this row
Clinton Bybee Common Stock, par value $0.0001 per share17.245,860,68109/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 4Open filing 0001012975-25-000773 Dispute this row
Robert Nelsen Common Stock, par value $0.0001 per share17.346,093,12509/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 4Open filing 0001012975-25-000773 Dispute this row
Steven Gillis Common Stock, par value $0.0001 per share17.245,860,68109/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 4Open filing 0001012975-25-000773 Dispute this row
Kristina Burow Common Stock, par value $0.0001 per share17.245,860,68109/30/2025 Filed 2025-11-14SCHEDULE 13G/AAmendment 4Open filing 0001012975-25-000773 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

2,099,622 filings read, dated 2004-06-14 to 2026-11-13: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
20151
2016204,322
2017202,494
2018202,048
2019193,638
2020144,184
2021224,474
202240,015
2023199,811
2024192,600
2025235,520
2026254,737

Filings made before the SEC required XML are listed, not extracted.

Back to SANA BIOTECHNOLOGY, INC.